Stephen Opat

List of Publications by Year in descending order

119 papers	6,492 citations	186265 28 h-index	69250 77 g-index
119 all docs	119 docs citations	119 times ranked	6126 citing authors

#	Article	IF	Citations
1	Obinutuzumab plus Chlorambucil in Patients with CLL and Coexisting Conditions. New England Journal of Medicine, 2014, 370, 1101-1110.	27.0	1,284
2	Venetoclax and Obinutuzumab in Patients with CLL and Coexisting Conditions. New England Journal of Medicine, 2019, 380, 2225-2236.	27.0	599
3	Obinutuzumab for the First-Line Treatment of Follicular Lymphoma. New England Journal of Medicine, 2017, 377, 1331-1344.	27.0	575
4	Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial. Lancet, The, 2019, 393, 229-240.	13.7	517
5	Whole transcriptome sequencing reveals recurrent NOTCH1 mutations in mantle cell lymphoma. Blood, 2012, 119, 1963-1971.	1.4	313
6	Tazemetostat for patients with relapsed or refractory follicular lymphoma: an open-label, single-arm, multicentre, phase 2 trial. Lancet Oncology, The, 2020, 21, 1433-1442.	10.7	306
7	A randomized phase 3 trial of zanubrutinib vs ibrutinib in symptomatic WaldenstrÃ¶m macroglobulinemia: the ASPEN study. Blood, 2020, 136, 2038-2050.	1.4	281
8	Phase 1 study of the selective BTK inhibitor zanubrutinib in B-cell malignancies and safety and efficacy evaluation in CLL. Blood, 2019, 134, 851-859.	1.4	259
9	Venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab for previously untreated chronic lymphocytic leukaemia (CLL14): follow-up results from a multicentre, open-label, randomised, phase 3 trial. Lancet Oncology, The, 2020, 21, 1188-1200.	10.7	208
10	Ibrutinib Plus Venetoclax for First-Line Treatment of Chronic Lymphocytic Leukemia: Primary Analysis Results From the Minimal Residual Disease Cohort of the Randomized Phase II CAPTIVATE Study. Journal of Clinical Oncology, 2021, 39, 3853-3865.	1.6	115
11	A multicentre retrospective comparison of central nervous system prophylaxis strategies among patients with high-risk diffuse large B-cell lymphoma. British Journal of Cancer, 2014, 111, 1072-1079.	6.4	113
12	ADAMTS13 Antibody Depletion by Bortezomib in Thrombotic Thrombocytopenic Purpura. New England Journal of Medicine, 2013, 368, 90-92.	27.0	110
13	Venetoclax and obinutuzumab in chronic lymphocytic leukemia. Blood, 2017, 129, 2702-2705.	1.4	108
14	The Recognition of HLA-B27 by Human CD4+ T Lymphocytes. Journal of Immunology, 2001, 167, 2619-2624.	0.8	106
15	Prognostic value of end-of-induction PET response after first-line immunochemotherapy for follicular lymphoma (GALLIUM): secondary analysis of a randomised, phase 3 trial. Lancet Oncology, The, 2018, 19, 1530-1542.	10.7	91
16	The BTK Inhibitor, Bgb-3111, Is Safe, Tolerable, and Highly Active in Patients with Relapsed/ Refractory B-Cell Malignancies: Initial Report of a Phase 1 First-in-Human Trial. Blood, 2015, 126, 832-832.	1.4	90
17	Fixed-duration ibrutinib plus venetoclax for first-line treatment of CLL: primary analysis of the CAPTIVATE FD cohort. Blood, 2022, 139, 3278-3289.	1.4	83
18	Zanubrutinib for the treatment of patients with WaldenstrÃ¶m macroglobulinemia: 3 years of follow-up. Blood, 2020, 136, 2027-2037.	1.4	78

#	Article	IF	Citations
19	Polatuzumab vedotin plus bendamustine and rituximab in relapsed/refractory DLBCL: survival update and new extension cohort data. Blood Advances, 2022, 6, 533-543.	5.2	77
20	Anti-CD20 monoclonal antibodies: reviewing a revolution. Human Vaccines and Immunotherapeutics, 2018, 14, 2820-2841.	3.3	68
21	Zanubrutinib for the treatment of relapsed or refractory mantle cell lymphoma. Blood Advances, 2021, 5, 2577-2585.	5.2	60
22	Bortezomib-based antibody depletion for refractory autoimmune hematological diseases. Blood Advances, 2016, 1, 31-35.	5.2	57
23	Zanubrutinib for the treatment of MYD88 wild-type WaldenstrÃ¶m macroglobulinemia: a substudy of the phase 3 ASPEN trial. Blood Advances, 2020, 4, 6009-6018.	5.2	57
24	Rituximab is associated with improved survival for aggressive B cell CNS lymphoma. Neuro-Oncology, 2013, 15, 1068-1073.	1.2	54
25	The MAGNOLIA Trial: Zanubrutinib, a Next-Generation Bruton Tyrosine Kinase Inhibitor, Demonstrates Safety and Efficacy in Relapsed/Refractory Marginal Zone Lymphoma. Clinical Cancer Research, 2021, 27, 6323-6332.	7.0	42
26	Ibrutinib (Ibr) Plus Venetoclax (Ven) for First-Line Treatment of Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL): Results from the MRD Cohort of the Phase 2 CAPTIVATE Study. Blood, 2019, 134, 35-35.	1.4	40
27	Obinutuzumab-Based Induction and Maintenance Prolongs Progression-Free Survival (PFS) in Patients with Previously Untreated Follicular Lymphoma: Primary Results of the Randomized Phase 3 GALLIUM Study. Blood, 2016, 128, 6-6.	1.4	40
28	Phase 2 Multicenter Study of Tazemetostat, an EZH2 Inhibitor, in Patients with Relapsed or Refractory Follicular Lymphoma. Blood, 2019, 134, 123-123.	1.4	33
29	The oral iron chelator deferasirox inhibits <scp>NF</scp>â€ºB mediated gene expression without impacting on proximal activation: implications for myelodysplasia and aplastic anaemia. British Journal of Haematology, 2015, 168, 576-582.	2.5	29
30	Clinical and Immunohistochemical Features Associated with a Response to Bortezomib in Patients with Multiple Myeloma. Clinical Cancer Research, 2009, 15, 714-722.	7.0	27
31	Failure of eculizumab to correct paroxysmal cold hemoglobinuria. Annals of Hematology, 2011, 90, 989-990.	1.8	27
32	Clinical pharmacology and PK/PD translation of the second-generation Brutonâ€™s tyrosine kinase inhibitor, zanubrutinib. Expert Review of Clinical Pharmacology, 2021, 14, 1329-1344.	3.1	27
33	Zanubrutinib for treatmentâ€naÃ¯ve and relapsed/refractory chronic lymphocytic leukaemia: longâ€term followâ€up of the phase I/II AUâ€003 study. British Journal of Haematology, 2022, 196, 1209-1218.	2.5	24
34	A practical guide to laboratory investigations at diagnosis and follow up in WaldenstrÃ¶m macroglobulinaemia: recommendations from the Medical and Scientific Advisory Group, Myeloma Australia, the Pathology Sub-committee of the Lymphoma and Related Diseases Registry and the Australasian Association of Clinical Biochemists Monoclonal Gammopathy Working Group. Pathology, 2020, 52, 167-178.	0.6	23
35	Efficacy and Safety of Zanubrutinib in Patients with Treatment-Naive Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) with Del(17p): Initial Results from Arm C of the Sequoia (BGB-3111-304) Trial. Blood, 2019, 134, 499-499.	1.4	23
36	Twice Daily Dosing with the Highly Specific BTK Inhibitor, Bgb-3111, Achieves Complete and Continuous BTK Occupancy in Lymph Nodes, and Is Associated with Durable Responses in Patients (pts) with Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL). Blood, 2016, 128, 642-642.	1.4	23

#	Article	IF	Citations
37	Failure of rituximab monotherapy in lymphomatoid granulomatosis. European Journal of Haematology, 2005, 75, 172-173.	2.2	22
38	SEQUOIA: Results of a Phase 3 Randomized Study of Zanubrutinib versus Bendamustine + Rituximab (BR) in Patients with Treatment-NaÃ¯ve (TN) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL). Blood, 2021, 138, 396-396.	1.4	22
39	Disseminated Enteroviral Infection Associated with Obinutuzumab. Emerging Infectious Diseases, 2015, 21, 1661-1663.	4.3	21
40	Head-To-Head Comparison Of Obinutuzumab (GA101) Plus Chlorambucil (Clb) Versus Rituximab Plus Clb In Patients With Chronic Lymphocytic Leukemia (CLL) and Co-Existing Medical Conditions (Comorbidities): Final Stage 2 Results Of The CLL11 Trial. Blood, 2013, 122, 6-6.	1.4	21
41	Obinutuzumab (GA101) plus chlorambucil (Clb) or rituximab (R) plus Clb versus Clb alone in patients with chronic lymphocytic leukemia (CLL) and preexisting medical conditions (comorbidities): Final stage 1 results of the CLL11 (BO21004) phase III trial.. Journal of Clinical Oncology, 2013, 31, 7004-7004.	1.6	20
42	Infusional dose-adjusted epoch plus bortezomib for the treatment of plasmablastic lymphoma. Annals of Hematology, 2016, 95, 667-668.	1.8	18
43	Treatment with the Bruton Tyrosine Kinase Inhibitor Zanubrutinib (BGB-3111) Demonstrates High Overall Response Rate and Durable Responses in Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): Updated Results from a Phase 1/2 Trial. Blood, 2019, 134, 500-500.	1.4	18
44	Results of the Safety Run-in Phase of CLL14 (BO25323): A Prospective, Open-Label, Multicenter Randomized Phase III Trial to Compare the Efficacy and Safety of Obinutuzumab and Venetoclax (GDC-0199/ABT-199) with Obinutuzumab and Chlorambucil in Patients with Previously Untreated CLL and Coexisting Medical Conditions. Blood, 2015, 126, 496-496.	1.4	17
45	Interim Results from an Ongoing Phase 2 Multicenter Study of Tazemetostat, an EZH2 Inhibitor, in Patients with Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL). Blood, 2018, 132, 4196-4196.	1.4	16
46	Allo-SCT for hematological malignancies in the setting of HIV. Bone Marrow Transplantation, 2010, 45, 584-586.	2.4	14
47	Refractory Bartonella quintana bacillary angiomatosis following chemotherapy for chronic lymphocytic leukaemia. Journal of Medical Microbiology, 2011, 60, 142-146.	1.8	14
48	Rapid and Durable Complete Remission of Refractory AITL with Azacitidine Treatment in Absence of TET2ÂMutation or Concurrent MDS. HemaSphere, 2019, 3, e187.	2.7	14
49	Risk profiling of patients with relapsed/refractory diffuse large B-cell lymphoma by measuring circulating tumor DNA. Blood Advances, 2022, 6, 1651-1660.	5.2	14
50	Bleeding and thrombotic events occur early in children on durable ventricular assist devices. Thrombosis Research, 2019, 173, 65-70.	1.7	13
51	ASPEN: Results of a phase III randomized trial of zanubrutinib versus ibrutinib for patients with WaldenstrÃ¶m macroglobulinemia (WM).. Journal of Clinical Oncology, 2020, 38, 8007-8007.	1.6	13
52	<scp>WhiMSICAL</scp>: A global WaldenstrÃ¶m's Macroglobulinemia patientâ€derived data registry capturing treatment and quality of life outcomes. American Journal of Hematology, 2021, 96, E218-E222.	4.1	12
53	Zanubrutinib monotherapy in relapsed/refractory indolent non-Hodgkin lymphoma. Blood Advances, 2022, 6, 3472-3479.	5.2	12
54	Disseminated echovirus infection after allogeneic bone marrow transplantation. Pathology, 1997, 29, 424-425.	0.6	10

#	Article	IF	Citations
55	Highâ€dose cytarabine (24â€‰g/m²) in combination with idarubicin (<scp>HiDAC</scp>â€3) results in high firstâ€cycle response with limited gastrointestinal toxicity in adult acute myeloid leukaemia. Internal Medicine Journal, 2013, 43, 294-297.	0.8	10
56	First-Line Treatment with Ibrutinib (Ibr) Plus Venetoclax (Ven) for Chronic Lymphocytic Leukemia (CLL): 2-Year Post-Randomization Disease-Free Survival (DFS) Results from the Minimal Residual Disease (MRD) Cohort of the Phase 2 Captivate Study. Blood, 2021, 138, 68-68.	1.4	10
57	Highâ€dose therapy and autologous stem cell transplantation may only be applicable to selected patients with secondary CNS diffuse large Bâ€cell lymphoma. British Journal of Haematology, 2017, 178, 991-994.	2.5	9
58	High Major Response Rate, Including Very Good Partial Responses (VGPR), in Patients (pts) with Waldenstrom Macroglobulinemia (WM) Treated with the Highly Specific BTK Inhibitor Bgb-3111: Expansion Phase Results from an Ongoing Phase I Study. Blood, 2016, 128, 1216-1216.	1.4	9
59	Integrated clinical and genomic evaluation of guadecitabine (SGI-110) in peripheral T-cell lymphoma. Leukemia, 2022, 36, 1654-1665.	7.2	9
60	Aplastic anaemia: autoimmune sequel of thymoma. British Journal of Haematology, 2009, 147, 591-591.	2.5	8
61	Guidelines for timely initiation of chemotherapy: a proposed framework for access to medical oncology and haematology cancer clinics and chemotherapy services. Internal Medicine Journal, 2016, 46, 964-969.	0.8	8
62	Cytarabine-based induction immunochemotherapy in the front-line treatment of older patients with mantle cell lymphoma. Scientific Reports, 2019, 9, 13544.	3.3	8
63	Frontâ€line management of indolent nonâ€Hodgkin lymphoma in Australia. Part 2: mantle cell lymphoma and marginal zone lymphoma. Internal Medicine Journal, 2019, 49, 1070-1080.	0.8	8
64	Venous thromboembolism in primary central nervous system lymphoma during frontline chemoimmunotherapy. Research and Practice in Thrombosis and Haemostasis, 2020, 4, 997-1003.	2.3	8
65	SAR245409 Monotherapy In Relapsed/Refractory Follicular Lymphoma: Preliminary Results From The Phase II ARD12130 Study. Blood, 2013, 122, 86-86.	1.4	8
66	Safety and Efficacy of Venetoclax and Obinutuzumab in Patients with Previously Untreated Chronic Lymphocytic Leukemia (CLL) and Coexisting Medical Conditions: Final Results of the Run-in Phase of the Randomized CLL14 Trial (BO25323). Blood, 2016, 128, 2054-2054.	1.4	8
67	Failure of tofacitinib to achieve an objective response in a DDX3X-MLLT10 T-lymphoblastic leukemia with activating JAK3 mutations. Journal of Physical Education and Sports Management, 2020, 6, a004994.	1.2	7
68	An Update on Safety and Preliminary Efficacy of Highly Specific Bruton Tyrosine Kinase (BTK) Inhibitor Zanubrutinib in Combination with PD-1 Inhibitor Tislelizumab in Patients with Previously Treated B-Cell Lymphoid Malignancies. Blood, 2019, 134, 1594-1594.	1.4	7
69	Azacitidine in Combination with the mTOR Inhibitor Everolimus in Relapsed and Refractory AML. Blood, 2011, 118, 2599-2599.	1.4	7
70	Preliminary Safety and Efficacy Data from Patients (Pts) with Relapsed/Refractory (R/R) B-Cell Malignancies Treated with the Novel B-Cell Lymphoma 2 (BCL2) Inhibitor BGB-11417 in Monotherapy or in Combination with Zanubrutinib. Blood, 2021, 138, 1419-1419.	1.4	7
71	Updated Safety and Activity of the Investigational Bruton Tyrosine Kinase Inhibitor Zanubrutinib (BGB-3111) in Patients with Mantle Cell Lymphoma. Blood, 2018, 132, 1592-1592.	1.4	6
72	Burkitt lymphoma in the setting of common variable immunodeficiency. Annals of Hematology, 2009, 88, 819-820.	1.8	5

#	Article	IF	Citations
73	Adaptive reprogramming of NK cells in X-linked lymphoproliferative syndrome. Blood, 2018, 131, 699-702.	1.4	5
74	A multicenter retrospective comparison of induction chemoimmunotherapy regimens on outcomes in transplantâ€eligible patients with previously untreated mantle cell lymphoma. Hematological Oncology, 2019, 37, 253-260.	1.7	5
75	Frontâ€line management of nonâ€Hodgkin lymphoma in Australia. Part 1: follicular lymphoma. Internal Medicine Journal, 2019, 49, 422-433.	0.8	5
76	Excellent outcomes in older patients with primary CNS lymphoma treated with R-MPV/cytarabine without whole brain radiotherapy or autologous stem cell transplantation therapy. Leukemia and Lymphoma, 2021, 62, 112-117.	1.3	5
77	Updated Report on Identification of Molecular Predictors of Tazemetostat Response in an Ongoing NHL Phase 2 Study. Blood, 2018, 132, 4097-4097.	1.4	5
78	Disease status at autologous stem cell transplantation and the cell of origin phenotype are important predictors of outcome in patients with neurologic (central nervous system) relapse of diffuse large B-cell lymphoma undergoing autologous stem cell transplantation. Leukemia and Lymphoma, 2009, 50, 1964-1968.	1.3	4
79	Incorporating High-Dose IV Methotrexate Into Initial Therapy Results In Lower Rates Of Central Nervous System (CNS) Relapse In Patients With High-Risk Diffuse Large B-Cell Lymphoma (DLBCL). Blood, 2013, 122, 4353-4353.	1.4	4
80	Whole Brain Radiotherapy and Ara-C In Consolidation Post High-Dose Methotrexate Is Important In Establishing Durable Disease Control In the Treatment of Primary CNS Lymphoma: A Single Centre Observational Study. Blood, 2010, 116, 1776-1776.	1.4	4
81	Haemopoietic Improvement Following Iron Chelation for Transfusional Haemosiderosis in Patients with Haematopoietic Neoplasia and Aplastic Anaemia: An Observational Study. Blood, 2011, 118, 5050-5050.	1.4	4
82	Associations between Smoking and Alcohol and Follicular Lymphoma Incidence and Survival: A Family-Based Case-Control Study in Australia. Cancers, 2022, 14, 2710.	3.7	4
83	Ibrutinib use, treatment duration, and concomitant medications in Australian patients with relapsed or refractory chronic lymphocytic leukaemia. British Journal of Haematology, 2022, 198, 790-793.	2.5	4
84	A drop of vitriol: microspherocytosis following sulphuric acid exposure. British Journal of Haematology, 2008, 140, 596-596.	2.5	3
85	Interim Report from a Phase 2 Multicenter Study of Tazemetostat, an EZH2 Inhibitor: Clinical Activity and Favorable Safety in Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma. Clinical Lymphoma, Myeloma and Leukemia, 2017, 17, S380-S381.	0.4	3
86	An update of venetoclax and obinutuzumab in chronic lymphocytic leukemia. Future Oncology, 2021, 17, 371-387.	2.4	3
87	Phase 2 Study of Zanubrutinib (BGB-3111) in Patients with Relapsed/Refractory Marginal Zone Lymphoma. Blood, 2019, 134, 5256-5256.	1.4	3
88	Interim Circulating Tumor DNA As a Prognostic Biomarker in the Setting of Interim PET-Based Adaptive Therapy for DLBCL. Blood, 2019, 134, 1600-1600.	1.4	3
89	Bortezomib Yields High Response Rates in Antibody-Mediated Autoimmune Hematological Diseases Refractory to Conventional Immunosuppression. Blood, 2015, 126, 3457-3457.	1.4	3
90	An unusual case of indigestion: persistence of phagocytosed Auer rods in acute promyelocytic leukaemia. British Journal of Haematology, 2006, 133, 112-112.	2.5	2

#	Article	IF	Citations
91	Factor XIII Assays. Methods in Molecular Biology, 2013, 992, 171-180.	0.9	2
92	Caution in Expanding the Use of Abbreviated R-CHOP to Poor-Risk Limited-Stage DLBCL. Journal of Clinical Oncology, 2020, 38, 4221-4222.	1.6	2
93	The 'Real World' Uptake and Prognostic Impact of GELF in Newly Diagnosed Follicular Lymphoma: An Australasian Alliance Initiative. Blood, 2019, 134, 3986-3986.	1.4	2
94	Allogeneic Peripheral Blood Stem Cell Transplantation for Hematological Malignancies in Patients with HIV.. Blood, 2007, 110, 4941-4941.	1.4	2
95	Number of Lymphoma-Associated-Macrophages (LAM) Is An Independent Predictor of Survival in Patients with Mantle Cell Lymphoma (MCL).. Blood, 2009, 114, 3944-3944.	1.4	2
96	An International Collaborative Study of Outcome and Prognostic Factors in Patients with Secondary CNS Involvement By Diffuse Large B-Cell Lymphoma. Blood, 2016, 128, 1874-1874.	1.4	2
97	Improved Survival of Older Patients with Mantle Cell Lymphoma (MCL) with Front-Line Cytarabine-Based Immunochemotherapy. Blood, 2016, 128, 2965-2965.	1.4	2
98	Antiplatelet therapy: present status and future prospects. Expert Opinion on Drug Discovery, 2007, 2, 1035-1040.	5.0	1
99	Oxidative haemolysis due to poppers. British Journal of Haematology, 2008, 142, 328-328.	2.5	1
100	Impact of coronavirus disease 2019 (COVID-19) pandemic isolation measures on the rate of nonâ€“COVID-19 infections in hematology patients. Infection Control and Hospital Epidemiology, 2021, 42, 233-235.	1.8	1
101	A Description of the Type, Frequency and Severity of Infections Among Sixteen Patients Treated for T-Cell Lymphoma. Journal of Hematology (Brossard, Quebec), 2021, 10, 123-129.	1.0	1
102	Safety of rapid injection of undiluted ferric carboxymaltose to patients with ironâ€deficiency anaemia: a <scp>Phase II</scp> singleâ€arm study. Internal Medicine Journal, 2021, 51, 1304-1311.	0.8	1
103	The Percentage of Cytotoxic T-Cells in Mantle Cell Lymphoma (MCL) Biopsies Predicts Response to Rituximab.. Blood, 2009, 114, 2923-2923.	1.4	1
104	Molecular Analysis of the SEC23B Gene In Patients Affected by Congenital Dyserythropoietic Anemia Type II (CDAII). Blood, 2010, 116, 4227-4227.	1.4	1
105	Salvage radiotherapy associates with durable response for a subset of patients with limited stage refractory DLBCL. Blood Advances, 2021, 5, 5112-5115.	5.2	1
106	Targeted Therapy in Leukaemia, Lymphoma and Myeloma. Journal of Personalized Medicine, 2022, 12, 74.	2.5	1
107	Bone marrow engraftment in pulmonary vessels. British Journal of Haematology, 2009, 146, 2-2.	2.5	0
108	The thrombotic thrombocytopenic purpura registry: a new national resource to inform patient care and medical research. Internal Medicine Journal, 2009, 39, 72-73.	0.8	0

#	Article	IF	Citations
109	A case of ITP with cauda equina syndrome. Annals of Hematology, 2011, 90, 729-730.	1.8	0
110	A national pathology review committee for the lymphoma and related diseases registry. Pathology, 2018, 50, S107.	0.6	0
111	Concurrent Mycobacterium tuberculosis infection and nodal marginal zone lymphoma. Pathology, 2018, 50, 464-466.	0.6	0
112	Excellent outcomes of transformed lymphomas in the rituximab era without autologous stem cell transplantation: an Australian singleâ€centre experience. Internal Medicine Journal, 2021, 51, 1825-1834.	0.8	0
113	The Clinical Utility of the 1-Deamino-8-D-Arginine Vasopressin (DDAVP) Trial in the Management of Patients with Von Willebrand Disease: A Retrospective Study.. Blood, 2006, 108, 1033-1033.	1.4	0
114	A Novel Fusion of RARA to the PRKAR1A Gene, Encoding the Regulatory Subunit Type-I Î± of Cyclic AMP Dependent Protein Kinase A, in a Variant Acute Promyelocytic Leukaemia.. Blood, 2006, 108, 2343-2343.	1.4	0
115	The Feasibility and Safety of Anticoagulation during Chemotherapy Associated Thrombocytopenia for Thrombotic Complications of Malignancy.. Blood, 2007, 110, 1872-1872.	1.4	0
116	The Utility of Radionuclide Ventriculography (RNV) Prior to Anthracycline Chemotherapy in Patients with Acute Myeloid Leukemia: A Retrospective, Single Institution Study.. Blood, 2007, 110, 4369-4369.	1.4	0
117	Real-World Outcomes of Patients with Primary CNS Lymphoma (PCNSL): A Report from the Australasian Lymphoma Alliance (ALA). Blood, 2021, 138, 2532-2532.	1.4	0
118	A Window Study of Acalabrutinib Plus Rituximab Followed By R-Dhaox (rituximab, dexamethasone,) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5 (MCL): The Australasian Leukaemia & Lymphoma Group (ALLG) NHL33 Wamm Trial. Blood, 2021, 138, 4516-4516.	1.4	0
119	Real World Data on the Outcomes of Richter's Transformation of Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma in the Australian Population: An Australasian Lymphoma Alliance Study. Blood, 2021, 138, 1455-1455.	1.4	0